NCT02040207View on ClinicalTrials.gov

AM-101 in the Treatment of Post-Acute Tinnitus 2

PHASE3CompletedINTERVENTIONAL

Enrollment

487

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Tinnitus

Interventions

DRUG

AM-101

AM-101 gel for intratympanic injection

Trial Locations (1)

Unknown

Investigational site, Munich

Sponsors

Lead Sponsor

Auris Medical AG

All Listed Sponsors

lead

Auris Medical AG

INDUSTRY

NCT02040207 - AM-101 in the Treatment of Post-Acute Tinnitus 2 | Biotech Hunter | Biotech Hunter